Latest Articles
Elise Mak
·
44 minutes ago
YZY Biopharma, of Wuhan, raised RMB200 million ($30 million) in Series Pre-C round to advance its bispecific antibodies and COVID vaccine candidates. More news from Zhiyi Biotech, HEP Pharma.
News
Elise Mak
·
6 hours ago
After two years of a biotech frenzy in China, entrepreneurs and investors need a cool head to stay afloat and be pragmatic to survive a frosty season.
Feature
Elise Mak
·
3 days ago
Shanghai startup NK CellTech closed a Series A round to raise over RMB100 million ($15 million) to help it advance its NK cell therapy pipeline and R&D. More news from Triastek.
News
Elise Mak
·
4 days ago
Vaccine developer Shanghai Rongsheng Biotech filed for an IPO with Shanghai's STAR board to raise over RMB1.25 billion ($186.7 million) with Essence Securities as its sponsor. More news from Winsunny, Allist, Akeso.
News
Danni Yin
·
4 days ago
The biotech deal making space in May 2022 saw Chinese drugmakers licensing out their assets for as much as a billion dollars. MSD and Turning Point Therapeutics gained China-originated cancer drugs in deals worth $2.63 billion.
China Deals Tracker
Elise Mak
·
5 days ago
Backed by CICC, Beijing Luzhu Biotechnology filed for an IPO in Hong Kong with plans to spend 40% of the proceeds on LZ901, a herpes zoster vaccine candidate. More news from Visum, Henlius, GenFleet, Bayer, Hengrui.
News
Elise Mak
·
5 days ago
Amgen announced a partnership with Fosun Pharma to commercialize Otezla and Parsabiv in mainland China. More news from BMS, Luzhu, LaNova, ImmuneOnco, Clover.
News
Elise Mak
·
7 days ago
Westlake Therapeutics, an Hangzhou-based biotech company that focuses on red blood cell (RBC)-based therapy, has closed its Series A+ funding led by Efung Capital to raise over RMB100 million ($15 million). More news from Genor, Abogen, Bayer, Innovent.
News
Sarina Yang
·
7 days ago
Chinese regulators have shared their considerations on selecting drugs for inclusion in state medical insurance, which should give drugmakers food for thought in terms of their strategy.
Regulatory
Elise Mak
·
10 days ago
Sino Biopharmaceuticals' subsidiary invoX Pharma acquired Nasdaq-listed biotech firm F-star Therapeutics for $161 million cash at $7.12 per share, as part of the effort to help the Chinese pharma giant dive deep in bispecifics in immunotherapy.
News